BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simsek M, Deben DS, Horjus CS, Bénard MV, Lissenberg-Witte BI, Buiter HJC, van Luin M, Seinen ML, Mulder CJJ, Wong DR, de Boer NKH, van Bodegraven AA. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther 2019;50:54-65. [PMID: 31094013 DOI: 10.1111/apt.15280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 van Asseldonk DP, Simsek M, de Boer NKH, Jharap B, Bloemena E, den Hartog G, Westerveld DB, Becx MC, Russel MG, Lissenberg-witte BI, van Nieuwkerk CM, Mulder CJJ, Verheij J, van Bodegraven AA. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients. Scandinavian Journal of Gastroenterology 2019;54:753-60. [DOI: 10.1080/00365521.2019.1629006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Rönnblom A, Ljunggren Ö, Karlbom U. Complications and adverse effects related to surgical and medical treatment in patients with inflammatory bowel disease in a prospectively recruited population-based cohort. Scand J Gastroenterol 2021;:1-8. [PMID: 34369245 DOI: 10.1080/00365521.2021.1961309] [Reference Citation Analysis]
3 Giraud EL, Thomas PWA, van Lint JA, van Puijenbroek EP, Römkens TEH, West RL, Russel MGVM, Jansen JM, Jessurun NT, Hoentjen F; IBDREAM registry. Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry. Drug Saf 2021;44:581-8. [PMID: 33538994 DOI: 10.1007/s40264-021-01045-3] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Simsek M, Deben DS, Horjus CS, Bénard MV, Lissenberg-Witte BI, Buiter HJC, van Luin M, Seinen ML, Mulder CJJ, Wong DR, de Boer NKH, van Bodegraven AA. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther 2019;50:54-65. [PMID: 31094013 DOI: 10.1111/apt.15280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
5 Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, Ansari A. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom. BMC Gastroenterol 2020;20:296. [PMID: 32917155 DOI: 10.1186/s12876-020-01441-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Zakerska-banaszak O, Łykowska-szuber L, Walczak M, Żuraszek J, Zielińska A, Skrzypczak-zielińska M. Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease. Toxics 2022;10:151. [DOI: 10.3390/toxics10040151] [Reference Citation Analysis]
7 Bayoumy AB, Mulder CJJ, Loganayagam A, Sanderson JD, Anderson S, Boekema PJ, Derijks LJJ, Ansari AR. Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine. Ther Drug Monit 2021;43:617-23. [PMID: 34521801 DOI: 10.1097/FTD.0000000000000869] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Biemans VBC, Savelkoul E, Gabriëls RY, Simsek M, Dijkstra G, Pierik MJ, West RL, de Boer NKH, Hoentjen F. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. Aliment Pharmacol Ther 2020;51:1076-86. [PMID: 32339331 DOI: 10.1111/apt.15730] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
10 Bayoumy AB, Simsek M, Seinen ML, Mulder CJJ, Ansari A, Peters GJ, De Boer NK. The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review. Expert Opin Drug Metab Toxicol 2020;16:111-23. [PMID: 32090622 DOI: 10.1080/17425255.2020.1719996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Bayoumy AB, Crouwel F, Chanda N, Florin THJ, Buiter HJC, Mulder CJJ, de Boer NKH. Advances in Thiopurine Drug Delivery: The Current State-of-the-Art. Eur J Drug Metab Pharmacokinet 2021. [PMID: 34487330 DOI: 10.1007/s13318-021-00716-x] [Reference Citation Analysis]